ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL460026
CHEMBL460026
Compound Name ICOSAPENT
ChEMBL Synonyms ICOSAPENT | OMEGA-3 MARINE TRIGLYCERIDES | eicosapentaenoic acid
Max Phase 3
Trade Names
Molecular Formula C20H30O2

Additional synonyms for CHEMBL460026 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O
Standard InChI InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17 ...
Download InChI
Standard InChI Key JAZBEHYOTPTENJ-JLNKQSITSA-N

Sources

  • Gene Expression Atlas Compounds
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names

Alternate Forms of Compound in ChEMBL


CHEMBL460026

Molecule Features

CHEMBL460026 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Unclassified Parenteral:Unclassified Topical:Unclassified Black Box:Unclassified Availability Type:Unclassified

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
AdenomaD000236EFO:0005406colorectal adenoma2ClinicalTrials
Adenomatous Polyposis ColiD011125EFO:0000662polyp2ClinicalTrials
AgingD000375GO:0007568aging1ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
CarcinomaD002277EFO:0000313carcinoma3ClinicalTrials
Carcinoma, DuctalD044584EFO:0000430ductal adenocarcinoma2ClinicalTrials
Heart FailureD006333EFO:0003144heart failure3ClinicalTrials
Liver DiseasesD008107EFO:0001421liver disease3ClinicalTrials
Lupus Erythematosus, SystemicD008180EFO:0002690systemic lupus erythematosus2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer2ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm2ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:0003095non-alcoholic fatty liver disease2ClinicalTrials
ObesityD009765EFO:0001073obesity3ClinicalTrials
Phobia, SocialD000072861EFO:1001917social anxiety disorder2ClinicalTrials
SchizophreniaD012559EFO:0000692schizophrenia2ClinicalTrials
Substance-Related DisordersD019966EFO:0003890drug dependence2ClinicalTrials
Wounds and InjuriesD014947EFO:0000546injury2ClinicalTrials
Death, Sudden, CardiacD016757EFO:0004278sudden cardiac arrest1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma2ClinicalTrials
InflammationD007249MP:0001845inflammation2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma1ClinicalTrials
Tachycardia, VentricularD017180EFO:0005306ventricular tachycardia1ClinicalTrials
Fatty LiverD005234HP:0001397Hepatic steatosis2ClinicalTrials
LeukemiaD007938EFO:0000565leukemia1ClinicalTrials
Tobacco Use DisorderD014029EFO:0003768nicotine dependence3ClinicalTrials
Adenomatous Polyposis ColiD011125Orphanet:733Familial adenomatous polyposis2ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression3ClinicalTrials
Digestive System DiseasesD004066EFO:0000405digestive system disease3ClinicalTrials
Glomerulonephritis, IGAD005922EFO:0004194IGA glomerulonephritis3ClinicalTrials
Breast Neoplasms, MaleD018567EFO:0006861male breast carcinoma2ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease3ClinicalTrials
HypertriglyceridemiaD015228EFO:0004211Hypertriglyceridemia3ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Mental DisordersD001523EFO:0000677mental or behavioural disorder2ClinicalTrials
Movement DisordersD009069EFO:0004280movement disorder2ClinicalTrials
Psychotic DisordersD011618EFO:0005411schizoaffective disorder2ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease3ClinicalTrials
EpilepsyD004827EFO:0000474epilepsy2ClinicalTrials
Hepatitis C, ChronicD019698EFO:0004220Chronic Hepatitis C infection2ClinicalTrials
HyperlipidemiasD006949EFO:0003774hyperlipidemia1ClinicalTrials
Kidney DiseasesD007674EFO:0003086kidney disease0ClinicalTrials
LymphomaD008223EFO:0000574lymphoma1ClinicalTrials
Lymphoma, FollicularD008224EFO:0000096neoplasm of mature B-cells2ClinicalTrials
Multiple SclerosisD009103EFO:0003885multiple sclerosis2ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease2ClinicalTrials
Retinopathy of PrematurityD012178EFO:1001158retinopathy of prematurity2ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis3ClinicalTrials
AsthmaD001249EFO:0000270asthma2ClinicalTrials
Bipolar DisorderD001714EFO:0000289bipolar disorder2ClinicalTrials
Child Development Disorders, PervasiveD002659EFO:0003756autism spectrum disorder2ClinicalTrials
Coronary Artery DiseaseD003324EFO:0000378coronary artery disease3ClinicalTrials

Clinical Data

ClinicalTrials.gov ICOSAPENT
The Cochrane Collaboration ICOSAPENT

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL460026. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL2069 Thromboxane A2 receptor Homo sapiens 1.000
CHEMBL1835 Thromboxane-A synthase Homo sapiens 1.000
CHEMBL4427 Prostanoid DP receptor Homo sapiens 1.000
CHEMBL1987 Prostanoid FP receptor Homo sapiens 1.000
CHEMBL2488 Prostanoid EP2 receptor Mus musculus 1.000
CHEMBL1881 Prostanoid EP2 receptor Homo sapiens 1.000
CHEMBL2489 Prostanoid EP4 receptor Mus musculus 1.000
CHEMBL3250 Lysophosphatidic acid receptor Edg-7 Homo sapiens 1.000
CHEMBL4336 Prostanoid EP3 receptor Mus musculus 0.996
CHEMBL4086 Prostanoid EP4 receptor Rattus norvegicus 0.992
CHEMBL1811 Prostanoid EP1 receptor Homo sapiens 0.992
CHEMBL1836 Prostanoid EP4 receptor Homo sapiens 0.988
CHEMBL3911 Leukotriene B4 receptor 1 Homo sapiens 0.980
CHEMBL3455 Anandamide amidohydrolase Mus musculus 0.933
CHEMBL4909 Prostanoid EP2 receptor Rattus norvegicus 0.926
CHEMBL3816 Cytosolic phospholipase A2 Homo sapiens 0.918
CHEMBL2181 Prostanoid EP1 receptor Mus musculus 0.906
CHEMBL3724 Lysophosphatidic acid receptor Edg-4 Homo sapiens 0.752
CHEMBL3037 Cannabinoid CB1 receptor Mus musculus 0.673
CHEMBL3819 Lysophosphatidic acid receptor Edg-2 Homo sapiens 0.663



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2069 Thromboxane A2 receptor Homo sapiens 1.000
CHEMBL1628461 Oxoeicosanoid receptor 1 Homo sapiens 1.000
CHEMBL1835 Thromboxane-A synthase Homo sapiens 1.000
CHEMBL4427 Prostanoid DP receptor Homo sapiens 1.000
CHEMBL1987 Prostanoid FP receptor Homo sapiens 1.000
CHEMBL2488 Prostanoid EP2 receptor Mus musculus 1.000
CHEMBL1881 Prostanoid EP2 receptor Homo sapiens 1.000
CHEMBL2489 Prostanoid EP4 receptor Mus musculus 1.000
CHEMBL3250 Lysophosphatidic acid receptor Edg-7 Homo sapiens 1.000
CHEMBL4336 Prostanoid EP3 receptor Mus musculus 1.000
CHEMBL2181 Prostanoid EP1 receptor Mus musculus 1.000
CHEMBL1811 Prostanoid EP1 receptor Homo sapiens 0.999
CHEMBL1995 Prostanoid IP receptor Homo sapiens 0.999
CHEMBL3724 Lysophosphatidic acid receptor Edg-4 Homo sapiens 0.997
CHEMBL3344 Fatty acid binding protein muscle Homo sapiens 0.996
CHEMBL1836 Prostanoid EP4 receptor Homo sapiens 0.993
CHEMBL3911 Leukotriene B4 receptor 1 Homo sapiens 0.986
CHEMBL4086 Prostanoid EP4 receptor Rattus norvegicus 0.984
CHEMBL3710 Prostanoid EP3 receptor Homo sapiens 0.977
CHEMBL3816 Cytosolic phospholipase A2 Homo sapiens 0.961

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
302.5 302.2246 5.99 13 37.3 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
1 1 1 2 1 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.75 - 6.5 3.88 0 22 0.33

Structural Alerts

There are 4 structural alerts for CHEMBL460026. To view alerts please click here.

Compound Cross References

ChemSpider ChemSpider:JAZBEHYOTPTENJ-JLNKQSITSA-N
PubChem SID: 144205544 SID: 26754924 SID: 26754925 SID: 50110832
Wikipedia Eicosapentaenoic_acid

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL460026



ACToR 10417-94-4
Atlas eicosapantaenoic acid
BindingDB 50242349
Brenda 16892 9998 41642 2992 215747 20256 5496 126492
ChEBI 28364
DrugBank DB00159
DrugCentral 3174
eMolecules 509162
EPA CompTox Dashboard DTXSID9041023
FDA SRS AAN7QOV9EA
Guide to Pharmacology 3362
Human Metabolome Database HMDB0001999
KEGG Ligand C06428
LINCS LSM-42964
LipidMaps LMFA01030759
Metabolights MTBLC28364
MolPort MolPort-003-933-180
Nikkaji J343.473G
PDBe EPA
PharmGKB PA164746077
PubChem 446284
PubChem: Thomson Pharma 14776226
SureChEMBL SCHEMBL20469
ZINC ZINC000004474603

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/JAZBEHYOTPTENJ-JLNKQSITSA-N spacer
spacer